Galecto Inc
GLTO
View Detailed Chart
5.420USD
-0.540-9.06%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
7.18MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-9.06%
5 Days
-24.30%
1 Month
+43.01%
6 Months
+81.27%
Year to Date
+16.56%
1 Year
-19.47%
View Detailed Chart
TradingKey Stock Score of Galecto Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galecto Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
6.000
Target Price
+99.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Galecto Inc Highlights
StrengthsRisks
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Undervalued
The company’s latest PE is -0.56, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 164.42K shares, decreasing 47.70% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.54K shares of this stock.
Galecto Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Galecto Inc Info
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Ticker SymbolGLTO
CompanyGalecto Inc
CEODr. Hans T. Schambye, M.D., Ph.D.
Websitehttps://galecto.com/
Related Instruments
+1.78%
0.00%
0.00%
-0.38%
+0.17%
+0.08%
+0.48%
0.00%
0.00%
+0.74%
-0.33%
0.00%
+0.26%
0.00%
+0.26%
-0.01%
0.00%
0.00%
-0.04%
0.00%Popular Symbols
